Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLUTION trial of sacubitril/valsartan after catheter ablation in non-paroxysmal atrial fibrillation
ChiCTR2500102523Phase 4Recruiting
- Sponsor
- Changzhou Wujin People's Hospital
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sacubitril + valsartan in Atrial fibrillation (AFib) and hypertension (HTN) (2 arms), sponsored by Changzhou Wujin People's Hospital. Primary endpoint: Freedom from AF or AT/AFL 12 months post-ablation after the 3-month blanking period. Started May 2025; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
Atrial fibrillation (AFib)hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2500102523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102523.